AB1033 MEASUREMENT OF DISEASE ACTIVITY LEVEL OVER TIME IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS UNDER BIOLOGIC TREATMENT, USING THE JUVENILE DISEASE ACTIVITY SCORE HUNGARIAN DATA FROM THE JUVENILE IDIOPATHIC ARTHRITIS REGISTRY OF THE NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY. (June 2019)

• Record Type: Journal Article
• Authors: Orbán, Ilonka; Sevcic, Krisztina; Kiss, Emese Virág; Poór, Gyula
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1981
• Page End: 1982
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.7611
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: A wide variety of measures are currently available to monitor the disease course over time in children with JIA.The Juvenile Disease Activity Score JADAS71 version was validated for 71 joints, global score for the JADAS71 is: 0-101. Objectives: To report the changes of disease activity in JIA patients under biological treatment at age 18, using the JADAS 71 score for the extended oligoarticular and seropositive/seronegative polyarticular form of JIA. Methods: The Hungarian Biologics JIA Registry of National Institute of Rheumatology and Physiotherapy, Budapest is a longitudinal, unicenter, observational study, that has been maintained since 2002. JIA-ILAR criteria were used for the diagnosis.Patients with polyarticular course, who failed to respond or did not tolerate methotrexate and were treated with biological agents at the Paediatric Rheumatologic Centre of the National Institute of Rheumatology and Physiotherapy, Budapest, Hungary from 2002 to 25th January, 019, were enrolled in an open label observational study and have been monitored prospectively in the registry. At baseline patients and disease characteristics were registered such as, patients' history, demographic characteristics, and previous DMARDs treatments. Adverse events(AEs), reason for the discontinuation of the biologic treatment, or switch to another biological treatment were documented. The study was approved by the Institutional Review Board. Written informed consent was obtained from parents of the patients and the study was conducted in accordance with the Declaration of Helsinki. Results: In this study 64, 18-year-old Caucasian JIA patients were evaluated from the day of entrance into the registry, who had JADAS 71 results at age 18, from the 347 patients treated with biologics at the submission. Demographic data and disease related variables by descriptive statistics: Gender: Female: N(%): 49(77%). Subtypes of JIA: Extended oligoarticular form: 11 patients, Polyarticular form: 53 patients (5 RF positive, 48 negative) Median age: 8 (range:4-17) years. Mean disease duration: 3352 days. Mean time on biological treatment:1030 days. The first JADAS 71 summation at the entry into the registry: Median: 18, 65 (range:14, 4-55, 4). The age 18 JADAS71 summation: Median:3, 75 (range: 2, 1-38). All patients were under biologic treatment (etanercept: 56, adalimumab: 29, tocilizumab: 12, abatacept: 4 patients). Disease activity states and responses to treatments: Conclusion: It appears from our study that at age 18, 72, 3% JIA patients with extended oligoarticular subtype and 26, 4% with polyarticular subtypes report a JADAS71 high disease activity sum, so, these young adults will need transitional care. References: [1] Consolaro A et.al. Arthritis Rheum. 2009;61:658–66. Acknowledgement: Tamás Balázs statistical analysis. Disclosure of Interests: None declared